Global Medications for Alcohol Use Disorder (AUD) Market Growth (Status and Outlook) 2024-2030

Global Medications for Alcohol Use Disorder (AUD) Market Growth (Status and Outlook) 2024-2030

Alcohol use disorder (AUD), is a chronic condition characterized by an inability to control alcohol consumption despite negative consequences. It involves a physical and psychological dependence on alcohol, where individuals may experience cravings, withdrawal symptoms, and a persistent desire to drink. Medications for Alcohol Use Disorder (AUD) are an important component of treatment, helping individuals manage cravings, reduce alcohol consumption, and maintain sobriety. Currently, commonly used drugs include naltrexone, acamprosate, etc.

The global Medications for Alcohol Use Disorder (AUD) market size is projected to grow from US$ million in 2024 to US$ million in 2030; it is expected to grow at a CAGR of %from 2024 to 2030.

LPI (LP Information)' newest research report, the “Medications for Alcohol Use Disorder (AUD) Industry Forecast” looks at past sales and reviews total world Medications for Alcohol Use Disorder (AUD) sales in 2022, providing a comprehensive analysis by region and market sector of projected Medications for Alcohol Use Disorder (AUD) sales for 2023 through 2029. With Medications for Alcohol Use Disorder (AUD) sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Medications for Alcohol Use Disorder (AUD) industry.

This Insight Report provides a comprehensive analysis of the global Medications for Alcohol Use Disorder (AUD) landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Medications for Alcohol Use Disorder (AUD) portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Medications for Alcohol Use Disorder (AUD) market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Medications for Alcohol Use Disorder (AUD) and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Medications for Alcohol Use Disorder (AUD).

United States market for Medications for Alcohol Use Disorder (AUD) is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

China market for Medications for Alcohol Use Disorder (AUD) is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Europe market for Medications for Alcohol Use Disorder (AUD) is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Global key Medications for Alcohol Use Disorder (AUD) players cover Alkermes, Merck KGaA, Lundbeck, Alvogen, Mylan, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2023.

This report presents a comprehensive overview, market shares, and growth opportunities of Medications for Alcohol Use Disorder (AUD) market by product type, application, key players and key regions and countries.

Segmentation by Type:
Naltrexone
Acamprosate
Disulfiram
Other

Segmentation by Application:
Hospital
Rehabilitation Institutions
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

Segmentation by Type:
Naltrexone
Acamprosate
Disulfiram
Other

Segmentation by Application:
Hospital
Rehabilitation Institutions
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Alkermes
Merck KGaA
Lundbeck
Alvogen
Mylan
Teva
Sun Pharmaceutical Industries
Zydus Pharmaceuticals
Taj Pharmaceuticals
TAGI Pharma Inc.
Beijing Wellso Pharmaceutical Co
Glenmark Pharmaceuticals
Rusan Pharma Ltd

Please note: The report will take approximately 2 business days to prepare and deliver.